Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 14Sarcoma 1Genitourinary 1

Conditions

Sarcoma 39Leiomyosarcoma 10Osteosarcoma 8Breast Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neuroectodermal Tumors, Primitive, Peripheral 4Neoplasm Metastasis 4Melanoma 4Liposarcoma 4Histiocytoma, Malignant Fibrous 4Chondrosarcoma 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma, Synovial 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Hemangiosarcoma 3Esophageal Neoplasms 3Dermatofibrosarcoma 3Colorectal Neoplasms 3Bone Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Kaposi 2Rhabdomyosarcoma 2Recurrent Uterine Corpus Sarcoma 2Neuroblastoma 2

Interventions

trametinib 1sotorasib 1pembrolizumab 1palbociclib 1atezolizumab 1Pemetrexed 1Panitumumab 1Paclitaxel 1Everolimus 1Drug Therapy 1Docetaxel 1Carboplatin 1Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × Docetaxel × Sarcoma × Clear all
NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡